Bristol's $300 Mil. Settlement Leaves $170 Mil. In Reserve For Wholesaler Litigation
This article was originally published in The Pink Sheet Daily
Executive Summary
The company settles a securities class action related to wholesaler inventory accounting practices and Bristol's investment in ImClone's oncologic Erbitux. The settlement awaits final approval by Manhattan district court.
You may also be interested in...
Bristol Agrees To Continue Improving Financial Controls In Settling Shareholder Lawsuit
As part of proposed settlement of a derivative lawsuit, the company will continue to develop and implement oversight and disclosure policies that resulted from a 2004 settlement with SEC.
Bristol Agrees To Continue Improving Financial Controls In Settling Shareholder Lawsuit
As part of proposed settlement of a derivative lawsuit, the company will continue to develop and implement oversight and disclosure policies that resulted from a 2004 settlement with SEC.
Bristol Agrees To One-Month Inventory Limit Under SEC Settlement
Settlement marks first definition of "normal" inventory levels for pharmaceutical industry. Bristol agrees to $150 mil. civil penalty to resolve investigation into "channel stuffing" during 2000-2001.